What happens after first-line treatment for extensive-stage small cell lung cancer (ES-SCLC)?

Patient advocate Jill Feldman sits down with Dr. Martin Edelman, Chair of Hematology-Oncology at Fox Chase Cancer Center, to discuss maintenance therapy—also known as continuation therapy—and how it may help keep small cell lung cancer under control after initial treatment.

Dr. Edelman explains why small cell lung cancer is so difficult to treat, how immunotherapy has changed the treatment landscape, and why clinical trials remain critical to improving outcomes. He also shares practical advice for patients navigating treatment decisions, managing side effects, and balancing quality of life with ongoing care.

You'll learn:

• What maintenance therapy (continuation therapy) means in small cell lung cancer
• Why small cell lung cancer often returns after an initial response
• How immunotherapy is used after first-line treatment
• Which patients may benefit most from continuation therapy
• Why clinical trials should be discussed early in treatment
• Important questions to ask your oncologist
• The role of supportive and palliative care in improving quality of life
• What gives experts hope for the future of small cell lung cancer treatment

Whether you're newly diagnosed, currently in treatment, or supporting a loved one, this conversation offers practical guidance and hope from one of the leading experts in thoracic oncology.

Learn more about lung cancer research, treatment options, and patient resources at lcfamerica.org.

Dr. Martin Edelman, MD – Fox Chase Cancer Center

Dr. Martin Edelman is Chair of Hematology-Oncology at Fox Chase Cancer Center and a nationally recognized thoracic oncologist. Throughout his career, he has helped advance treatment options for lung cancer patients through clinical research, immunotherapy development, and patient-centered care.

Jill Feldman – Lung Cancer Patient Advocate and Host

Jill Feldman is a lung cancer survivor, advocate, and nationally recognized voice in the lung cancer community. Through education and advocacy, she helps patients and families navigate diagnosis, treatment decisions, and survivorship.

Show Notes: https://lcfamerica.org/wp-content/uploads/2026/06/LCFA-HWA-Maintenance-Therapy-Show-Notes.pdf Transcript: https://lcfamerica.org/wp-content/uploads/2026/06/LCFA-HWA-Maintenance-Therapy-Transcript.pdf YouTube: https://youtu.be/IRf6uF18tTQ

Subscribe to Hope With Answers: Living With Lung Cancer podcast for future episodes on your favorite listening platform.

What is PD-L1, and why does it matter so much in your lung cancer treatment plan? Patient host Colette Smith talks with Dr. Julie Brahmer of Johns Hopkins University Hospital to demystify PD-L1 testing, immunotherapy decisions, and personalized lung cancer care.

You'll learn:

• What PD-L1 is and how cancer cells use it as a "cloaking device"
• How Tumor Proportion Scores (TPS) from 0 to 100 guide treatment choices
• When immunotherapy alone works—and when chemotherapy should be added
• Why repeat biopsies matter for long-term survivors
• The most common side effects of immunotherapy and how they're managed
• When immunotherapy may not be the right option
• Key questions to ask your oncologist at every stage of treatment
• Why every patient should ask about clinical trials

Whether you're newly diagnosed or navigating a treatment change, this conversation offers clarity, hope, and actionable guidance.

Get the full PD-L1 guide and download free patient resources: https://lcfamerica.org/about-lung-cancer/diagnosis/understand-pd-l1/

Heading to a doctor's appointment? Download LCFA's "Questions to Ask Your Care Team about PD-L1" PDF at lcfamerica.org.

Learn more at lcfamerica.org.

Guests:

• Dr. Julie Brahmer, Johns Hopkins University Hospital
• Colette Smith, Patient Host

Show Notes - https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-HWA-PD-L1-in-Lung-Cancer-Show-Notes.pdf Transcript - https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-HWA-PDL1-Transcript.pdf YouTube - https://youtu.be/Ymff6MwaJTc

Subscribe to Hope With Answers: Living With Lung Cancer podcast for future episodes on your favorite listening platform.

Three years after her small cell lung cancer diagnosis, patient advocate Wendy Brooks sits down with Dr. Ashish Saxena, medical oncologist at Weill Cornell Medicine, to talk about the rapid changes transforming SCLC care. From immunotherapy and bispecific T-cell engagers to emerging targeted therapies, this episode unpacks what every patient should know about today's treatment landscape.

You'll learn why clinical trials are NOT a last resort, why you should ask about them at your very first appointment, and how to advocate for yourself through side effects and treatment decisions. Dr. Saxena also explains the evolving role of biomarker testing in small cell lung cancer and shares why he's more hopeful than ever about patient outcomes.

Whether you're newly diagnosed, a long-term survivor, or a caregiver, this conversation delivers honest answers and real hope.

Guests:

Dr. Ashish Saxena, Medical Oncologist, Weill Cornell Medicine

Wendy Brooks, Patient Co-Host, Living with Small Cell Lung Cancer

Show Notes: https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-SCLC-Clinical-Trials-Long-Term-Outlook-Show-Notes.pdf

Transcript: https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-HWA-SCLC-Clinical-Trials-Transcript.pdf

Video: https://youtu.be/RCwJvdcOS-4

For more information, visit lcfamerica.org.